SCHEMBL3378323

SCHEMBL3378323

ClN(Cl)CCc1c[nH]c2ccccc12

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 6/20 0.70
HTR1A P08908 5/20 0.70
HTR2C P28335 4/20 0.70
HTR2B P41595 3/20 0.70
HTR6 P50406 4/20 0.66
TRPM8 Q7Z2W7 1/20 0.62
TRPV1 Q8NER1 1/20 0.62
SLC6A4 P31645 2/20 0.61
CYP3A4 P08684 3/20 0.61
HTR1D P28221 2/20 0.61
HTR1B P28222 2/20 0.61
HTR7 P34969 2/20 0.61
CYP2D6 P10635 2/20 0.61
MPO P05164 1/20 0.61
CYP1A2 P05177 1/20 0.61
CYP2A6 P11509 1/20 0.61
NFKB1 P19838 1/20 0.61
CTSK P43235 1/20 0.61
CYP2A13 Q16696 1/20 0.61
TAAR1 Q96RJ0 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3380053 0.86 HTR2A (0.66) HTR2AHTR1AHTR2CHTR2BHTR6
SCHEMBL4985934 0.82 HTR2A (0.77) HTR2AHTR1AHTR2CHTR2BHTR6
SCHEMBL26688728 0.82 HTR2A (0.65) HTR2AHTR1AHTR2CHTR2BHTR6
SCHEMBL6933897 0.82 HTR2A (0.70) HTR2AHTR1AHTR2CHTR2BHTR6
N,N-Dimethyltryptamine SCHEMBL29350959 0.82 HTR2A (1.00) HTR2AHTR1AHTR2CHTR2BHTR6
SCHEMBL30896267 0.82 HTR2A (0.81) HTR2AHTR1AHTR2CHTR2BHTR6
N,N-Dimethyltryptamine SCHEMBL27221709 0.82 HTR2A (1.00) HTR2AHTR1AHTR2CHTR2BHTR6
N,N-Dimethyltryptamine SCHEMBL335710 0.82 HTR2A (1.00) HTR2AHTR1AHTR2CHTR2BHTR6
SCHEMBL3378673 0.82 HTR2A (0.70) HTR2AHTR1AHTR2CHTR2BHTR6
SCHEMBL6602711 0.82 HTR2A (0.70) HTR2AHTR1AHTR2CHTR2BHTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250354108-A1 METHODS FOR PRODUCING MONOTERPENE INDOLE ALKALOIDS UNIV DANMARKS TEKNISKE (DK) 2025-11-20 US disclosed
EP-4526426-A2 METHODS FOR PRODUCING MONOTERPENE INDOLE ALKALOIDS Danmarks Tekniske Universitet (DK) 2025-03-26 EP disclosed
WO-2023222879-A2 METHODS FOR PRODUCING MONOTERPENE INDOLE ALKALOIDS DANMARKS TEKNISKE UNIVERSITET (DK) 2023-11-23 WO disclosed
WO-2010017405-A1 METHODS AND COMPOSITIONS FOR THE TREATMENT OF PAIN HELLER ADAM (US) 2010-02-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250354108-A1 METHODS FOR PRODUCING MONOTERPENE INDOLE ALKALOIDS INMT, KARS1, MIA3 HTR2A 2339/4885HTR1A 2720/4885HTR2C 2595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.